Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 2/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.71 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.71 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14441049 | 1.00 | OPRD1 (0.71) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL12018148 | 1.00 | OPRD1 (0.71) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL4576661 | 1.00 | OPRD1 (0.71) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL14343545 | 1.00 | OPRD1 (0.71) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL12017985 | 0.94 | OPRD1 (0.76) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL12017979 | 0.93 | OPRD1 (0.72) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL12018160 | 0.93 | OPRD1 (0.72) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL3111930 | 0.93 | OPRD1 (0.72) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL4576944 | 0.93 | OPRD1 (0.72) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL4576255 | 0.93 | OPRD1 (0.72) | OPRD1CYP1A2CYP3A4CYP2C9HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210220349-A1 | DELTA OPIOID AGONIST, MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSONS DISEASE | DMK PHARMACEUTICALS CORPORATION | 2021-07-22 | — | — | US | disclosed |
| US-10973815-B2 | Delta opioid agonist mu opioid antagonist compositions and methods for treating Parkinsons disease | VERSI GROUP, LLC (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190038620-A1 | DELTA OPIOID AGONIST MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSONS DISEASE | DMK PHARMACEUTICALS CORPORATION | 2019-02-07 | — | — | US | disclosed |
| EP-3436013-A1 | DELTA OPIOID AGONIST, MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE | Versi Group, LLC (US) | 2019-02-06 | — | — | EP | disclosed |
| US-10071093-B2 | Method of treating Parkinson's Disease with a diarylmethylpiperazine compounds exhibiting delta opioid receptor agonist activity | VERSI GROUP, LLC (US) | 2018-09-11 | — | — | US | disclosed |
| US-20170290823-A1 | METHOD OF TREATING PARKINSON'S DISEASE WITH A DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA OPIOID RECEPTOR AGONIST ACTIVITY | DMK PHARMACEUTICALS CORPORATION | 2017-10-12 | — | — | US | disclosed |
| WO-2017173067-A1 | DELTA OPIOID AGONIST, MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE | VERSI GROUP, LLC (US) | 2017-10-05 | — | — | WO | disclosed |
| US-9701645-B2 | Method of treating Parkinson's disease with a diarylmethylpiperazine compounds exhibiting delta opioid receptor agonist activity | VERSI GROUP, LLC (US) | 2017-07-11 | — | — | US | disclosed |
| US-20140315922-A1 | METHOD OF TREATING PARKINSON'S DISEASE WITH A DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA OPIOID RECEPTOR AGONIST ACTIVITY | VERSI GROUP, LLC (US) | 2014-10-23 | — | — | US | disclosed |
| US-8642599-B2 | Method of treating Parkinson's Disease with diarylmethylpiperazine compounds exhibiting delta receptor agonist activity | VERSI GROUP, LLC (US) | 2014-02-04 | — | — | US | disclosed |
| US-20070066625-A1 | METHOD OF TREATING PARKINSON'S DISEASE WITH DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA RECEPTOR AGONIST ACTIVITY | DMK PHARMACEUTICALS CORPORATION | 2007-03-22 | — | — | US | disclosed |
| WO-2007027987-A2 | METHOD OF TREATING PARKINSON'S DISEASE WITH DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA RECEPTOR AGONIST ACTIVITY | MOUNT COOK BIOSCIENCES, INC. (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10973815-B2 | Delta opioid agonist mu opioid antagonist compositions and methods for treating Parkinsons disease | OPRD1, OPRK1, OPRM1 | OPRD1 1/4885CYP1A2 989/4885CYP3A4 1116/4885 |
| US-20170290823-A1 | METHOD OF TREATING PARKINSON'S DISEASE WITH A DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA OPIOID RECEPTOR AGONIST ACTIVITY | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885CYP1A2 1084/4885CYP3A4 2300/4885 |
| US-20190038620-A1 | DELTA OPIOID AGONIST MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSONS DISEASE | OPRD1, OPRK1, OPRM1 | OPRD1 1/4885CYP1A2 989/4885CYP3A4 1116/4885 |
| US-10071093-B2 | Method of treating Parkinson's Disease with a diarylmethylpiperazine compounds exhibiting delta opioid receptor agonist activity | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885CYP1A2 1084/4885CYP3A4 2300/4885 |
| US-20140315922-A1 | METHOD OF TREATING PARKINSON'S DISEASE WITH A DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA OPIOID RECEPTOR AGONIST ACTIVITY | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885CYP1A2 1084/4885CYP3A4 2300/4885 |
| US-20210220349-A1 | DELTA OPIOID AGONIST, MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSONS DISEASE | OPRD1, OPRK1, OPRM1 | OPRD1 1/4885CYP1A2 1017/4885CYP3A4 1287/4885 |
| US-20070066625-A1 | METHOD OF TREATING PARKINSON'S DISEASE WITH DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA RECEPTOR AGONIST ACTIVITY | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885CYP1A2 894/4885CYP3A4 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.